Key result
JE-CV booster maintains 100% homologous seroprotection and high wild-type immunity in children at five years.
Why the study?
A genotype shift phenomenon in circulating Japanese encephalitis virus strains may affect vaccine-induced protection, necessitating assessment of long-term neutralization of wild-type strains after JE-CV vaccination.
Does a JE-CV booster induce long-term cross-neutralizing antibodies against wild-type Japanese encephalitis virus strains in children?
Does a JE-CV booster induce long-term cross-neutralizing antibodies against wild-type Japanese encephalitis virus strains in children?
Absolute Event Rate: 100% vs 91.5%
A JE-CV booster dose in toddlers induces long-term immune responses capable of neutralizing various wild-type Japanese encephalitis virus genotypes up to 5 years post-vaccination.
BACKGROUND: The live-attenuated Japanese encephalitis (JE) vaccine (JE-CV; IMOJEV) induces a protective response in children. A shift in circulating JE virus strains suggests that a genotype shift phenomenon may occur throughout Southeast Asia. We assessed the neutralization of wild-type (WT) JE virus isolates at distal time points after vaccination. METHODS: We analyzed serum samples from a subset of 47 children who had received a JE-CV booster after an inactivated JE vaccine primary immunization. We measured antibody titers (50% plaque reduction neutralization test) using a panel of WT JE strains at baseline, then after the booster at 28 days and 6 months in all subjects present at the time points and in a subset at year 5. Three additional recent isolates were tested at year 5. RESULTS: Of 47 subjects, 43 (91.5%) subjects had JE neutralizing antibody titers ≥10 (reciprocal serum dilution) against the homologous strain before JE-CV boost; all were seroprotected up to year 5 after the JE-CV boost. Baseline WT seroprotection ranged between 78.7% and 87.2%; all subjects were seroprotected against the 4 WT strains at 28 days and 6 months; year 5 seroprotection ranged between 95.7% and 97.9%. Similar rates of protection against 3 additional WT isolates were observed at year 5. CONCLUSIONS: The long-term immune responses induced after a JE-CV booster dose in toddlers were able to neutralize WT viruses from various genotypes circulating in Southeast Asia and India. CLINICAL TRIALS REGISTRATION: NCT00621764.
No takes yet. Share an insight, caveat, or question.
Feroldi et al. (2016) studied Japanese encephalitis (n=47). JE-CV booster (IMOJEV) vs. Baseline (pre-booster) was evaluated on JE neutralizing antibody titers ≥10 against the homologous strain. A JE-CV booster dose in children maintained 100% seroprotection against the homologous strain and 95.7% to 97.9% seroprotection against wild-type strains at 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: